Market research of the biologic and biosimilar drug segment in Poland
Industry
Biologic and biosimilar drug market
Geographical coverage
Poland
Client's need
For the purposes of a follow-up to the report "Biologic and biosimilar drug market in Poland", PMR's research department conducted research among management of companies dealing with biologic and biosimilar drugs in Poland. The project focused on assessing the situation and trends present in this specialised market. PMR conducted a study on a unique and relatively small market in Poland, and the report constitutes a useful business tool for professionals interested in the Polish pharmaceutical industry.
Our deliverables
A B2B study was conducted using CATI (computer-assisted telephone interviews). Due to a very small number of companies in the field, 21 interviews were carried out, out of 35 companies present in the market. In order to explore the topic in more detail, when possible, open-end questions were used, which let the respondents speak more freely. Because of this, the interviews gained qualitative insight and we gathered many interesting remarks which go a step beyond frequency distribution.
Value for the client
The study allowed us to identify the value of the biologic and biosimilar drug market, as well as the y-o-y dynamics.
The finished research report also contains data on the following topics, among others:
- opportunities and barriers in market development
- assessments from URPL (The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products) on activities pertaining to biological drugs
- trends in the biologic and biosimilar drugs market
- profiles of companies operating in the market.
The results became the basis for creating a report: "Biologic and biosimilar drug market in Poland"
